Compare RCUS & UTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCUS | UTF |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2018 | 2004 |
| Metric | RCUS | UTF |
|---|---|---|
| Price | $26.12 | $26.25 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $30.27 | N/A |
| AVG Volume (30 Days) | ★ 999.3K | 352.1K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $247,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $45.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.06 | $23.42 |
| 52 Week High | $26.40 | $27.33 |
| Indicator | RCUS | UTF |
|---|---|---|
| Relative Strength Index (RSI) | 65.38 | 49.91 |
| Support Level | $19.62 | $25.44 |
| Resistance Level | N/A | $26.28 |
| Average True Range (ATR) | 1.56 | 0.30 |
| MACD | 0.30 | -0.01 |
| Stochastic Oscillator | 69.54 | 21.98 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.